ReviewNanomaterials (Basel, Switzerland)2021
COVID-19 Pandemic: What about the Safety of Anti-Coronavirus Nanoparticles?
Review in Nanomaterials (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Identifying the Anti-MERS-CoV and Anti-HcoV-229E Potential Drugs from theMolecules (Basel, Switzerland) · 2023Article
- The current status of nanotechnological approaches to therapy and drug delivery in otolaryngology: A contemporary review.Laryngoscope investigative otolaryngology · 2022Review
- An exhaustive comprehension of the role of herbal medicines in Pre- and Post-COVID manifestations.Journal of ethnopharmacology · 2022Review
- Chemical Nature of Metals and Metal-Based Materials in Inactivation of Viruses.Nanomaterials (Basel, Switzerland) · 2022Review
- Inhibition of SARS-CoV-2 Alpha Variant and Murine Noroviruses on Copper-Silver Nanocomposite Surfaces.Nanomaterials (Basel, Switzerland) · 2022Article
- Antiviral Properties of Silver Nanoparticles against SARS-CoV-2: Effects of Surface Coating and Particle Size.Nanomaterials (Basel, Switzerland) · 2022Article
- The Potential Contribution of Biopolymeric Particles in Lung Tissue Regeneration of COVID-19 Patients.Polymers · 2021Review
- Current Potential Therapeutic Approaches against SARS-CoV-2: A Review.Biomedicines · 2021Review
- Unleashing the potential of cell membrane-based nanoparticles for COVID-19 treatment and vaccination.Expert opinion on drug delivery · 2021Article
- Copper-Silver Nanohybrids: SARS-CoV-2 Inhibitory Surfaces.Nanomaterials (Basel, Switzerland) · 2021Article
- Nanomedicine: A Diagnostic and Therapeutic Approach to COVID-19.Frontiers in medicine · 2021Review
- Restoration of olfactory dysfunctions by nanomaterials and stem cells-based therapies: Current status and future perspectives.Journal of tissue engineeringReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Every day, new information is presented with respect to how to best combat the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This manuscript sheds light on such recent findings, including new co-factors (i.e., neuropilin-1) and routes (i.e., olfactory transmucosal) allowing cell entry of SARS-CoV-2 and induction of neurological symptoms, as well as the new SARS-CoV-2 variants. We highlight the SARS-CoV-2 human-animal interfaces and elaborate containment strategies using the same vaccination (i.e., nanoparticle "NP" formulations of the BNT162b2 and mRNA-1273 vaccines) for humans, minks, raccoon dogs, cats, and zoo animals. We investigate the toxicity issues of anti-CoV NPs (i.e., plasmonic NPs and quantum dots) on different levels. Namely, nano-bio interfaces (i.e., protein corona), in vitro (i.e., lung cells) and in vivo (i.e., zebrafish embryos) assessments, and impacts on humans are discussed in a narrative supported by original figures. Ultimately, we express our skeptical opinion on the comprehensive administration of such antiviral nanotheranostics, even when integrated into facemasks, because of their reported toxicities and the different NP parameters (e.g., size, shape, surface charge, and purity and chemical composition of NPs) that govern their end toxicity. We believe that more toxicity studies should be performed and be presented, clarifying the odds of the safe administration of nanotoxocological solutions and the relief of a worried public.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.